ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions
View by Date

Sunday, November 7, 2021

8:30AM-10:30AM
Abstract Number: 0634
Correlation Between the Functional Component of the Multidimensional Health Assessment Questionnaire (FN), Modified Health Assessment Questionnaire (MHAQ), Health Assessment Questionnaire II (HAQ-II) and a Single Functional Question (PF) in Patients with Rheumatic Disease
Measures & Measurement of Healthcare Quality Poster (0623–0659)
8:30AM-10:30AM
Abstract Number: 0882
COVID-19 Impact Among Patients with Systemic Lupus Erythematosus
SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)
8:30AM-10:30AM
Abstract Number: 0646
Dark Adaptometry Screening for Hydroxychloroquine Retinopathy: A Pilot Study
Measures & Measurement of Healthcare Quality Poster (0623–0659)
8:30AM-10:30AM
Abstract Number: 0904
Data-driven Definitions Based on Inflammatory Lesions for a Positive MRI of the Spine Consistent with Axial Spondyloarthritis
Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster II: Imaging in Spondyloarthritis (0897–0907)
8:30AM-10:30AM
Abstract Number: 0736
Decrease in Prevalence of Self-Reported Anxiety or Depression in Persons with Osteoarthritis After Total Knee Arthroplasty: The BEST KNEE Cohort Study
Osteoarthritis – Clinical Poster II (0723–0738)
8:30AM-10:30AM
Abstract Number: 0775
Decreased HDL Levels and Antioxidant Function in Juvenile Dermatomyositis
Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)
8:30AM-10:30AM
Abstract Number: 0785
Decreased Peripheral Blood Natural Killer Cell Count in Untreated Juvenile Dermatomyositis Is Associated with Muscle Weakness
Pediatric Rheumatology – Clinical Poster II: SLE, JDM, & Juvenile Scleroderma (0764–0785)
8:30AM-10:30AM
Abstract Number: 0655
Depression and Fatigue: Two Forgotten Associated Comorbidities in Patients with Rheumatoid Arthritis
Measures & Measurement of Healthcare Quality Poster (0623–0659)
8:30AM-10:30AM
Abstract Number: 0890
Depression Is Associated with Frailty in Systemic Lupus Erythematosus Patients: Multicenter Retrospective Analysis Using Systemic Lupus Erythematosus International Collaborating Clinics-Frailty Index
SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)
8:30AM-10:30AM
Abstract Number: 0697
Detection of Autoantibodies Against Muscle-Specific Four-and-a-Half-LIM Domain 1 (FHL1) in Inflammatory Myopathies: Results from a Single-Center Cohort
Muscle Biology, Myositis & Myopathies Poster (0683–0722)
8:30AM-10:30AM
Abstract Number: 0886
Determinants of Accessing Social and News Media and Experiencing Negative Impacts During COVID-19 in an International SLE Sample
SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)
8:30AM-10:30AM
Abstract Number: 0567
Determinants of Health-Related Quality of Life in Spondyloarthritis and Comparison with Chronic Low Back Pain – Results from a Nation-Wide Study
Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)
8:30AM-10:30AM
Abstract Number: 0532
Development of a Predictive Tool for the Rapid Progressive Knee Osteoarthritis Phenotype: Data from the Osteoarthritis Initiative
Genetics, Genomics & Proteomics Poster (0517–0533)
8:30AM-10:30AM
Abstract Number: 0761
Development of a Symptom Diary for Use in Patients with Sjogren’s Syndrome
Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)
8:30AM-10:30AM
Abstract Number: 0524
Development of Biomarker Models to Identify HLA-related Microbiome Associations in Anti-Ro+ Mothers of Children with Neonatal Lupus
Genetics, Genomics & Proteomics Poster (0517–0533)
  • «Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 34
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology